Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.

Annals of the American Thoracic Society is a premier journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by the American Thoracic Society, this journal offers an invaluable platform for researchers and clinicians to disseminate cutting-edge research, clinical insights, and innovative methodologies. With an impressive impact factor and ranked in the top Q1 category of its field (2023) and within the top 20 of 155 according to Scopus rankings, it is positioned as a leading force in shaping clinical practice and research directions. The journal's convergence years from 2013 to 2024 indicate a commitment to providing timely and relevant content at the forefront of pulmonary health. While not an open-access journal, it ensures broad accessibility to its significant contributions in respiratory medicine, making it an essential resource for professionals, researchers, and students alike endeavoring to deepen their understanding and improve outcomes in thoracic health.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

Turkish Thoracic Journal, published by AVES, is a prominent open-access platform dedicated to advancing the field of pulmonary and respiratory medicine. Since its establishment, the journal has aimed to disseminate significant research findings, clinical studies, and reviews that contribute to an improved understanding of respiratory health challenges, with a particular focus on the Turkish context and regional issues. With an E-ISSN of 2149-2530 and transitioning to open access in 2022, the journal enhances visibility and accessibility, inviting a global audience of researchers, clinicians, and students to engage with the latest scientific work. The Turkish Thoracic Journal has been indexed in major databases, although it faced a coverage discontinuation in Scopus between 2016 and 2022. Currently positioned within the 23rd percentile among its peers in the field, it invites submissions that explore innovative approaches to thoracic health, enriching the discourse in a vital area of medicine.

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

EXPERIMENTAL LUNG RESEARCH, published by Taylor & Francis Inc, is a pivotal journal within the field of pulmonary and respiratory medicine, with its extensive coverage spanning from 1980 to 2024. The journal is indexed with ISSN 0190-2148 and E-ISSN 1521-0499, marking its commitment to disseminating high-quality research. With its Category Quartile rankings falling within Q3 in Clinical Biochemistry, Molecular Biology, and Pulmonary and Respiratory Medicine as of 2023, EXPERIMENTAL LUNG RESEARCH serves as a crucial platform for researchers and professionals seeking to explore innovative findings and advancements in lung physiology, pathology, and therapeutic approaches. Although currently not Open Access, it offers substantial insights through rigorous peer-reviewed articles that contribute significantly to the scientific community's understanding of respiratory health. With Scopus rankings reflecting its relevance within its categories, this journal attracts a diverse readership interested in advancing the field of lung research.

Respiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.

CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.